Cargando…

Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity

Simultaneous inhibition of more than one target is considered to be a novel strategy in cancer therapy. Owing to the importance of histone deacetylases (HDACs) and p53-murine double minute 2 (MDM2) interaction in tumor development and their synergistic effects, a series of MDM2/HDAC bifunctional sma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Qian, Xiong, Shan-Shan, Chen, Can, Zhu, Hong-Ping, Xie, Xin, Peng, Cheng, He, Gu, Han, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386376/ https://www.ncbi.nlm.nih.gov/pubmed/35992773 http://dx.doi.org/10.3389/fonc.2022.972372

Ejemplares similares

Corrigendum: Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity
por: Zhao, Qian, et al.
Publicado: (2023)

Rational drug design, synthesis, and biological evaluation of novel chiral tetrahydronaphthalene-fused spirooxindole as MDM2-CDK4 dual inhibitor against glioblastoma
por: Wang, Biao, et al.
Publicado: (2020)

Structure-based discovery of a novel small-molecule inhibitor of TEAD palmitoylation with anticancer activity
por: Gridnev, Artem, et al.
Publicado: (2022)

Editorial: Discovery of small molecule lead compounds: A driving force to unravel new anticancer targets and mechanisms
por: Zhang, Yan, et al.
Publicado: (2023)

Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics
por: Matias-Barrios, Victor M., et al.
Publicado: (2021)

Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents
por: Cincinelli, Raffaella, et al.
Publicado: (2018)

Synthesis of a New Class of Spirooxindole–Benzo[b]Thiophene-Based Molecules as Acetylcholinesterase Inhibitors
por: Barakat, Assem, et al.
Publicado: (2020)

Substituted spirooxindole derivatives as potent anticancer agents through inhibition of phosphodiesterase 1
por: Barakat, Assem, et al.
Publicado: (2018)

Design, Synthesis, Chemical and Biochemical Insights Into Novel Hybrid Spirooxindole-Based p53-MDM2 Inhibitors With Potential Bcl2 Signaling Attenuation
por: Aziz, Yasmine M. Abdel, et al.
Publicado: (2021)

MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy
por: Miles, Xanthene, et al.
Publicado: (2021)

Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy
por: Wu, Donglu, et al.
Publicado: (2020)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
por: Booth, Laurence, et al.
Publicado: (2019)

Application of In Silico Filtering and Isothermal Titration Calorimetry for the Discovery of Small Molecule Inhibitors of MDM2
por: Alali, Hen, et al.
Publicado: (2022)

Stereoselective Synthesis of the Di-Spirooxindole Analogs Based Oxindole and Cyclohexanone Moieties as Potential Anticancer Agents
por: Al-Majid, Abdullah Mohammed, et al.
Publicado: (2021)

Discovery of a cytochrome P450 enzyme catalyzing the formation of spirooxindole alkaloid scaffold
por: Nguyen, Tuan-Anh M., et al.
Publicado: (2023)

Discovery of N-(2-Amino-4-Fluorophenyl)-4-[bis-(2-Chloroethyl)-Amino]-Benzamide as a Potent HDAC3 Inhibitor
por: Chen, Yiming, et al.
Publicado: (2020)

Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells
por: Roberts, Jane L., et al.
Publicado: (2021)

A One-Pot Three-Component Synthesis and Investigation of the In Vitro Mechanistic Anticancer Activity of Highly Functionalized Spirooxindole-Pyrrolidine Heterocyclic Hybrids
por: Kumar, Raju Suresh, et al.
Publicado: (2020)

Optimized spirooxindole-pyrazole hybrids targeting the p53-MDM2 interplay induce apoptosis and synergize with doxorubicin in A549 cells
por: Islam, Mohammad Shahidul, et al.
Publicado: (2023)

Construction of Spirooxindole Analogues Engrafted with Indole and Pyrazole Scaffolds as Acetylcholinesterase Inhibitors
por: Islam, Mohammad Shahidul, et al.
Publicado: (2021)

Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment
por: Zhou, Maojun, et al.
Publicado: (2021)

Discovery of BRAF/HDAC Dual Inhibitors Suppressing Proliferation of Human Colorectal Cancer Cells
por: Li, Yingjun, et al.
Publicado: (2022)

Transition metal-catalyzed synthesis of spirooxindoles
por: Saranya, P. V., et al.
Publicado: (2021)

Synthesis of Spirooxindole-O-Naphthoquinone-Tetrazolo[1,5-a]Pyrimidine Hybrids as Potential Anticancer Agents
por: Wu, Liqiang, et al.
Publicado: (2018)

Synthesis, Characterization, and Cytotoxicity of New Spirooxindoles Engrafted Furan Structural Motif as a Potential Anticancer Agent
por: Altowyan, Mezna Saleh, et al.
Publicado: (2022)

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
por: Zhong, Mengya, et al.
Publicado: (2021)

DIMP53‐1: a novel small‐molecule dual inhibitor of p53–MDM2/X interactions with multifunctional p53‐dependent anticancer properties
por: Soares, Joana, et al.
Publicado: (2017)

The anticancer effects of HDAC inhibitors require the immune system
por: West, Alison C, et al.
Publicado: (2014)

The function of natural compounds in important anticancer mechanisms
por: Nan, Yang, et al.
Publicado: (2023)

MDM2 inhibitors-mediated disruption of mitochondrial metabolism: A novel therapeutic strategy for retinoblastoma
por: Romani, Arianna, et al.
Publicado: (2022)

Design and synthesis of new spirooxindole candidates and their selenium nanoparticles as potential dual Topo I/II inhibitors, DNA intercalators, and apoptotic inducers
por: El-Kalyoubi, Samar, et al.
Publicado: (2023)

Small molecule MMRi62 targets MDM4 for degradation and induces leukemic cell apoptosis regardless of p53 status
por: Lama, Rati, et al.
Publicado: (2022)

The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors
por: Kannan, Srinivasaraghavan, et al.
Publicado: (2019)

Canagliflozin, characterized as a HDAC6 inhibitor, inhibits gastric cancer metastasis
por: Jiang, Dandan, et al.
Publicado: (2022)

High-Throughput Strategies for the Discovery of Anticancer Drugs by Targeting Transcriptional Reprogramming
por: Huang, Lijun, et al.
Publicado: (2021)

Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies
por: Shetu, Shaila A., et al.
Publicado: (2022)

Hybrid molecules of protoflavones and spirooxindole derivatives with selective cytotoxicity against triple-negative breast cancer cells
por: Girst, Gábor, et al.
Publicado: (2023)

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
por: Zhu, Haohao, et al.
Publicado: (2022)

Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule
por: Grinkevich, Vera V., et al.
Publicado: (2022)

Synergistic Rescue of Nonsense Mutant Tumor Suppressor p53 by Combination Treatment with Aminoglycosides and Mdm2 Inhibitors
por: Zhang, Meiqiongzi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_541cg6at6d26ubkrstgt97avf8